MDM2 and hepatocellular carcinoma: This activation has been carried out by multiple mechanisms: (1) MTBP is co-amplified with c-MYC and functions as c-Myc’s co-activator (50); (2) MTBP could enhance the activation of ZEB2 to induce the EMT process of cancerous cells (13); (3) MTBP inhibits the apoptosis of cancer cells via suppression of the MDM2/P53 axis (14); and (4) MTBP can enhance the metastasis of HCC cells via the MDM2-Mediated E-Cadherin Degradation (11).